Nucleic Acid, Nucleoside, or Nucleotide – Page 3

Eli Lilly Expands Pipeline with Strategic Deals in MASH and Cancer Therapies

2 months ago talkbio0Tagged AdvanCell, alpha therapies, Cancer Therapeutic Procedure, cardiometabolic diseases, cellular targeting, Eli, Eli Lilly, Interferes with, MASH, OliX, Radiopharmaceuticals, RNA

Eli Lilly, OliX Pharmaceuticals, AdvanCell, MASH, targeted alpha therapies, radiopharmaceuticals, RNA interference, cardiometabolic diseases, cancer treatment

NHS England Approves Groundbreaking CRISPR Gene Therapy for Sickle Cell Disease

3 months ago talkbio0Tagged Anemia, Sickle Cell, Approved, Casgevy, Clustered Regularly Interspaced Short Palindromic Repeats, England, exagamglogene autotemcel, gene therapy, Nance-Horan syndrome, NICE, Nitroglycerin/Sodium Citrate/Ethanol Solution

Casgevy, exagamglogene autotemcel, CRISPR gene therapy, sickle cell disease, NHS England, Vertex Pharmaceuticals, NICE approval

HHS Awards Moderna $590 Million to Expedite Bird Flu Vaccine Development

3 months ago talkbio0Tagged Aves, CHARGE Syndrome, Moderna, mRNA Vaccine, pandemic preparedness, Vaccines

Moderna, HHS, Bird Flu Vaccine, Avian Influenza, mRNA Vaccine, Pandemic Preparedness

FDA Places Clinical Hold on Atara Biotherapeutics’ EBVALLO and ATA3219 Due to Manufacturing Compliance Issues

3 months ago talkbio0Tagged allogeneic T-cell therapies, Atara Biotherapeutics, Biomechanical compliance, Ebvallo, Epstein-Barr virus, GMP, Guanosine Monophosphate, Lupus Erythematosus, Systemic, Manufacturing, Post-transplant lymphoproliferative disorder, Study on Hold, United States Food and Drug Administration

Atara Biotherapeutics, FDA clinical hold, EBVALLO, ATA3219, allogeneic T-cell therapies, manufacturing compliance issues, GMP compliance, Epstein-Barr virus, post-transplant lymphoproliferative disease, non-Hodgkin’s lymphoma, systemic lupus erythematosus.

Sanofi Assures No Supply Disruptions Following FDA Warning Letter for US Manufacturing Site

3 months ago talkbio0Tagged Cautionary Warning, Cyclic GMP, deviations, interruptions, Letter [Publication Type], manufacturing site, sanofi, U.S., United States Food and Drug Administration

Sanofi, FDA warning letter, US manufacturing site, supply interruptions, CGMP deviations

Moderna Co-Founder Kenneth Chien’s New Biotech Secures $950M RNA Deal with Etherna

3 months ago talkbio0Tagged Chien, deal, Etherna, Kenneth, Moderna, mRNA therapies, RNA

Kenneth Chien, Moderna, Etherna, RNA deal, biotech, mRNA therapies

Intellia Therapeutics Slashes Workforce by 27% to Focus on Late-Stage CRISPR Candidates Amid Challenging Market Environment

3 months ago talkbio0Tagged Amyloidosis, Angioedema, ATTR, Clustered Regularly Interspaced Short Palindromic Repeats, Commercialization strategy, Hereditary, Intellia, Late stage, nex-z, Nexiguran, NTLA-2002, Prealbumin, Workforce

Intellia Therapeutics, CRISPR, Workforce reduction, Late-stage drug candidates, NTLA-2002, Nexiguran ziclumeran (nex-z), Hereditary angioedema, Transthyretin (ATTR) amyloidosis, Commercialization strategy